dapsone / Generic mfg. - LARVOL DELTA

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States (ASH 2025) - "Following the initial ITP diagnosis, previously treated patients were identified as those who were currently on ITP treatment and who had received one prior therapy comprising an oral corticosteroid, IVIG, IV anti-D, or platelet transfusion, as well as one or more prior therapies comprising TPO-RA, rituximab, fostamatinib, anti-CD-38 monoclonal antibodies, immunosuppressants, danazol, dapsone, bortezomib, vinca alkaloid, or splenectomy. Conclusions Despite receiving at least one currently available first-line and second-line therapy, in this US-based claims study of patients with primary ITP, a significant proportion continued to experience bleeding events and required rescue therapy. This analysis highlights significant unmet needs for novel therapies for the primary ITP patient population."

Retrospective data • Gynecology • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

P017 A multifaceted case of pyoderma gangrenosum: insights into diagnosis and management in the presence of comorbid conditions. (PubMed, Br J Dermatol) - "She initially presented with a large ulcerative lesion that was misdiagnosed as a fungal infection and treated unsuccessfully with terbinafine...The patient's treatment journey involved multiple immunosuppressive therapies, such as prednisolone and ciclosporin, although ciclosporin was later discontinued due to kidney complications. She was also treated with mycophenolate mofetil, which was halted after it aggravated her diverticular disease, and with dapsone, which was eventually stopped due to liver-related concerns...She is currently under close, multidisciplinary monitoring and is awaiting approval for biologic therapy with risankizumab, which her gastroenterology team favours over infliximab because of liver concerns...Biologic therapies, although currently restricted, represent a promising option for refractory PG. Continuous collaboration among specialists, careful monitoring of treatment impacts on comorbidities, and further research into biologic efficacy..."

Journal • Autoimmune Hepatitis • Dermatology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Nephrology • Pain • Pyoderma Gangrenosum • Renal Disease • Septic Shock • Thrombocytopenia

P097 Atypical pemphigoid and an acneiform eruption in a patient with inflammatory bowel disease. (PubMed, Br J Dermatol) - "The differential diagnosis included fungal and bacterial infections, and his scalp responded to terbinafine and ciprofloxacin, with partial improvement of his face and trunk...He responded rapidly to high-dose oral prednisolone, which was tapered over 3 months...His working diagnosis is two concurrent conditions: an atypical pemphigoid and a separate acneiform/pustular eruption possibly on the pyoderma gangrenosum-hidradenitis suppurativa spectrum in the context of irritable bowel disease. He is now well controlled on dapsone and doxycycline, with isotretinoin added recently, given an overarching clinical feature of an acneiform eruption at present."

Journal • Acne Vulgaris • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pyoderma Gangrenosum • Ulcerative Colitis

BG09 Acquired haemophilia A in mucous membrane pemphigoid: beware of spontaneous bleeding in immunobullous diseases. (PubMed, Br J Dermatol) - "MMP was suspected, and treatment was initiated with prednisolone (10 mg once daily), doxycycline (200 mg once daily) and dapsone (50 mg once daily)...Prednisolone was increased to 20 mg once daily and dapsone was replaced with mycophenolate mofetil (MMF) 1 g twice daily, but there was no significant improvement...Prednisolone was increased to 50 mg once daily, MMF was continued and tranexamic acid was added to support clotting...A number of dermatological conditions have been associated with AHA, including immunobullous and autoimmune diseases. Screening for AHA should be undertaken in dermatology patients with autoimmune diagnoses who develop spontaneous or unusual bleeding."

Journal • Dermatology • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases • Respiratory Diseases

HX02 From arsenic to rituximab: a history of dermatitis herpetiformis. (PubMed, Br J Dermatol) - "The first major breakthrough came in 1950, when it was recognized that dapsone immediately abolished the itch and rash, and it became the mainstay of treatment. Rituximab has been reported to cause complete remission. Ongoing research into the immunopathogenesis of DH may lead to more targeted treatments."

Journal • Celiac Disease • CNS Disorders • Dermatitis • Dermatology • Immunology • Mental Retardation • Psychiatry

P118 A retrospective analysis of rituximab prescribing for 38 patients with pemphigus over a 10-year period in a tertiary immunobullous clinic: should we be using rituximab as first-line therapy for moderate and severe pemphigus? (PubMed, Br J Dermatol) - "Second-line treatment was with mycophenolate mofetil in 76% (n = 29), azathioprine in 7% (n = 3) and dapsone in 5% (n = 2). Third-line treatments included azathioprine, dapsone and methotrexate...Of these, 85% were still taking prednisone and/or mycophenolate mofetil at 6 months, with further reduction and cessation of these medications documented over a longer timeframe...Our real clinic findings highlight the management of patients with severe or recalcitrant pemphigus. The results are corroborated by the increasing body of convincing medical evidence suggesting that earlier administration of rituximab for pemphigus is both safer and more efficacious than standard therapy and make a case for earlier use of rituximab in this challenging cohort."

Journal • Retrospective data • Dermatology • Immunology • Pemphigus Vulgaris

PA43 An infrequently diagnosed cause of pruritus. (PubMed, Br J Dermatol) - "Treatment with tetracycline antibiotics or dapsone has been shown to reduce the duration of the inflammatory phase. The residual hyperpigmentation usually persists for many months. This case is presented to enhance awareness, and facilitate early identification and appropriate treatment of this characteristic inflammatory dermatosis."

Journal • Anorexia • Bulimia • Dermatology • Diabetes • Inflammation • Metabolic Disorders • Pruritus

BG13 Pemphigoid vegetans of the buttocks. (PubMed, Br J Dermatol) - "A variety of treatment modalities have been reported in the literature, including topical corticosteroids, dapsone, tetracyclines and systemic steroids (Kim J, Chavel S, Girardi M, McNiff JM. J Cutan Pathol 2008; 35: 1144-7). However, the rarity of this condition necessitates further discussion to optimize management strategies."

Journal • Bullous Pemphigoid • CNS Disorders • Dermatology • Dermatopathology • Eosinophilia • Immunology • Inflammation

P040 Clinical features, treatment and treatment response of 24 patients with epidermolysis bullosa acquisita. (PubMed, Br J Dermatol) - "All patients were treated initially with oral prednisolone and some patients required oral dapsone (n = 20), intravenous corticosteroids (n = 11), mycophenolate mofetil (n = 19) and azathioprine (n = 7). Overall, 63% (n = 15) of patients were treated with intravenous immunoglobulin (IVIG) and 63% (n = 15) with rituximab...In conclusion, the treatment of EBA can be challenging, and most patients in this series required combination treatment with corticosteroids, dapsone and an intravenous immunosuppressant. The treatment-refractory nature of the disease is also reflected by the high proportion of patients requiring rituximab, and 25% of patients having ongoing active disease despite maximal therapy."

Journal

P027 A case of cutaneous nodules in a migrant man. (PubMed, Br J Dermatol) - "The infectious disease team treated him for multibacillary leprosy with dapsone, rifampicin, clofazimine and steroids. Leprosy is a neglected tropical disease that is under-recognized in Europe, resulting in treatment delay. This is a unique case of leprosy in Ireland, which demonstrates the utility of cutaneous findings and skin biopsy in attaining a diagnosis."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Sarcoidosis • CRP

P048 Lenalidomide use in recalcitrant inflammatory dermatoses: a trio of successes. (PubMed, Br J Dermatol) - "A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses."

Journal • Cardiovascular • Cataract • Dental Disorders • Dermatology • Discoid Lupus Erythematosus • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Oncology • Ophthalmology • Pain • Peripheral Neuropathic Pain • Rheumatology • Stomatitis • Systemic Lupus Erythematosus • Thrombocytopenia • IL12A • IL6

P030 From nerve to nodules: the unexpected progression of pure neuritic leprosy to lepromatous leprosy with erythema nodosum leprosum. (PubMed, Br J Dermatol) - "The patient was started on World Health Organization-recommended multidrug therapy with rifampicin, dapsone and clofazimine for 12 months...The patient was started on a regimen of monthly pulsed rifampicin, minocycline and moxifloxacin for 12 months. Thalidomide was started to manage the severe ENL reaction...Only one such case has been previously reported. This emphasizes the need for early diagnosis, vigilant follow-up and awareness of potential disease transformations, particularly in endemic areas."

Journal • Dermatology • Immune Modulation • Immunology • Infectious Disease • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

BG11 Neutrophilic dermatosis: an unexpected pathway to diagnosing rheumatoid arthritis in a 73-year-old woman. (PubMed, Br J Dermatol) - "Treatment with oral prednisolone, 30 mg daily for 1 week, with a slow taper and dapsone 100 mg once daily was commenced. This case highlights the challenges in managing neutrophilic dermatosis in older patients, particularly when complicated by comorbidities. The patient's evolving clinical picture, including the possibility of rheumatoid arthritis contributing to both her skin and pulmonary manifestations, underscores the importance of a multidisciplinary approach in diagnosing and managing complex dermatological cases in older patients."

Journal • Cardiovascular • Cough • Dermatology • Dyslipidemia • Fatigue • Fibrosis • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Ischemic stroke • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • CRP

Efficacy and safety of dapsone in adult immune thrombocytopenia: a systematic review and meta-analysis. (PubMed, Eur J Med Res) - "Dapsone demonstrates moderate efficacy and an acceptable safety profile in adult ITP patients, especially in resource-limited contexts. While it may not match thrombopoietin agonists in preventing relapse, its low cost and oral administration offer practical advantages. Further large-scale randomized trials are warranted to clarify its role in ITP management."

Journal • Retrospective data • Review • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Tense bullae in a pediatric patient. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Immunology • Pediatrics

Update on cutaneous lupus erythematosus pathogenesis, diagnosis and management. (PubMed, J Eur Acad Dermatol Venereol) - "Antimalarials, particularly hydroxychloroquine, remain the cornerstone of systemic therapy. Second-line or third-line agents such as methotrexate, retinoids, dapsone, thalidomide and lenalidomide are recommended in refractory cases. Biological therapies, including belimumab and anifrolumab, are approved in the setting of SLE. Promising results from recent trials of targeted therapies including inhibitors of plasmacytoid dendritic cells, TLR7/8 and TYK2 are paving the way for novel treatment strategies in CLE."

Journal • Review • Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • TLR7 • TYK2

A Red Lobulated Facial Mass: A Clinicopathological Challenge. (PubMed, Int J Dermatol) - "The condition was refractory to initial methotrexate and isotretinoin therapy. We report a rare and clinically challenging case of RDD diagnosed with the aid of histopathology and immunohistochemistry. Additionally, we emphasize the role of a combined approach of serial surgical excisions and systemic dapsone therapy."

Journal • Dermatofibrosarcoma Protuberans • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Rare Diseases • Sarcoidosis • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • TNFRSF8

Multifocal and extrafacial chronic violaceous plaques. (PubMed, JAAD Case Rep) - No abstract available

Journal

Cotton gauze wound-dressing patches loaded with dapsone derivative and silver nanoparticles for promoting wound healing via antibacterial acceleration function. (PubMed, RSC Adv) - "The ability of cotton-gauze-loaded material to serve as a bactericidal agent was also evaluated compared to reference antibiotics using standard microbial skin pathogens. Interestingly, a significant reduction in bacterial growth, particularly in the case of Bacillus cereus, followed by Pseudomonas aeruginosa and Staphylococcus aureus, was clearly dependent on the concentration and release rate of the loaded-AgNPs/gel."

Journal • Infectious Disease

Comparative Risk of Acute Anemia and Urinary Tract Infection With Sulfamethoxazole-Trimethoprim Versus Dapsone After Kidney Transplant. (PubMed, Ann Pharmacother) - "The risk of anemia was twofold higher in KTRs who received dapsone compared with SMX-TMP but did not appear to affect the rates of erythropoiesis-stimulating agent use or blood transfusion. There was no difference in the risk of UTI. These findings may inform agent selection and monitoring of prophylaxis for opportunistic infection in KTRs."

Journal • Anemia • Hematological Disorders • Infectious Disease • Nephrology • Transplantation

Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study (ASH 2023) - "Among them, 75 (55.6%) patients were treated with only corticosteroids +/- intravenous immunoglobulin, 52 (38.5%) with rituximab, 2 with splenectomy, and 1 with dapsone...Among them, 46 (88.5%) patients were treated as first-line with a rituximab-cyclophosphamide-dexamethasone combined regimen, 2 with rituximab-bendamustine, 2 with chloraminophen, 1 with fludarabine-cyclophosphamide-dexamethasone, and 1 with ibrutinib...Whatever the strategy used (treating AIC only or also using chemotherapy for the IBC), the effectiveness and safety profiles of first-line treatments were not different. Additional analyses are ongoing to better clarify the impact of rituximab alone versus rituximab and chemotherapy, and IBC’ characteristics on the overall progression-free survival."

Clinical • Amyloidosis • Anemia • Autoimmune Hemolytic Anemia • Chronic Lymphocytic Leukemia • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Waldenstrom Macroglobulinemia

Multiclass Method to Analyze Banned Veterinary Drugs in Casings by LC-MS/MS: A Validation Study According to Regulation (EU) 2021/808. (PubMed, J Agric Food Chem) - "The metabolites of seven nitrofurans, seven nitroimidazoles, chloramphenicol, and dapsone were simultaneously identified and quantified by the developed standard operating procedure, which was successfully validated according to the criteria of the Commission Implementing Regulation (EU) 2021/808, using the regulatory limits or levels of interest in force in Europe. The reliability of the method has been demonstrated by the analysis of proficiency testing reference materials. Additional data on a challenged nitrofuran marker residue are discussed."

Journal

Good Prognosis of Adult Immune Thrombocytopenia in a Provincial Hospital (ASH 2023) - "The first-line treatment consisted of dexamethasone (70...4% of cases, including colchicine (60. 7%), azathioprine (35. 7%), cyclophosphamide (25%), dapsone (17. 8%), vincristine (10. 7%), mycophenolate mofetil (7. 1%), cyclosporine (3. 5%), and/or eltrombopag (3... This study reveals a favorable prognosis for ITP, with a majority of patients showing sustained response (CR+R), which differs from findings in studies conducted at referral centers. Female patients and those with primary ITP are more likely to respond. Further confirmation is needed through a large prospective cohort study in community hospitals."

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura

Systemic Erythema Elevatum Diutinum Overlapping with Hypocomplementemic Urticarial Vasculitis (ISDS 2025) - "Dapsone, a first-line EED therapy, did not clinically improve cutaneous or systemic symptoms. Methotrexate was subsequently initiated; efficacy remains to be determined... This case emphasizes the importance of recognizing EED as a potentially systemic condition that may present with articular manifestations and raises consideration of overlap with HUV. It also highlights the therapeutic complexity of managing systemic EED, particularly when conventional treatments fail to achieve adequate disease control."

Dermatitis • Dermatology • Immunology • Musculoskeletal Pain • Urticaria • Vasculitis

Transcriptome-Guided Treatment in Refractory Acne Fulminans: A Case Report (ISDS 2025) - "Over a four-year period, conventional (isotretinoin, antibiotics, and dapsone) and off-label treatments (TNF-α and interleukin 17A inhibitors, and TYK2 blockade) failed to achieve sustained improvement...Based on these molecular signatures, off-label treatment with the pan-JAK inhibitor tofacitinib (10 mg/day) was initiated... This case highlights the potential of transcriptomic profiling to identify treatable pathways and guide personalized management in severe, treatment-refractory inflammatory diseases, where standard diagnostic and therapeutic approaches are insufficient."

Case report • Clinical • Acne Vulgaris • Atopic Dermatitis • Cushing’s Disease • Dermatitis • Dermatology • Endocrine Disorders • Immunology • Inflammation • Musculoskeletal Pain • Psoriasis • IL17A • JAK1 • TNFA • TYK2